Bayer outlined its strategy to return to growth leveraging new product launches as revenues from established drugs like Xarelto and Eylea plateau. The German pharma aims to replenish its portfolio through innovation and pipeline advancement to offset waning sales in mature segments. This plan comes amidst broader industry challenges including patent cliffs and market competition, positioning Bayer for a transformational recovery in the midterm.